Live news related to CROSSJECT stock (FR0011716265): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
The latest financial news on CROSSJECT mainly cover analyst notes, M&A activity et guidance and outlook. The stock trades at €1,30 on Euronext Paris, down 2,11% at the last update. This page lists the articles published on CROSSJECT stock to track the share price, company announcements and any item likely to influence market perception.
The €15 million capital increase completed in May 2026 reshapes Crossject's financial structure. The Dijon-based company, which is developing the need…
Crossject's supervisory board has appointed three new members to the management board, which now comprises five people. This development comes as the …
The Dijon-based laboratory, specialized in needle-free auto-injectors, announced the consolidation of its pediatric development plan for Zepizure, in …
Crossject's stock significantly declines mid-day, following the announcement of a major financing operation aimed to accelerate the development of its…
Crossject announced on Friday the successful completion of a capital increase and the issuance of warrants for a total amount of 15 million euros. Thi…
Oddo BHF révise sa position sur Crossject ce vendredi 27 mars 2026.
Crossject has announced the appointment of Lionel Seltz as Chief Financial Officer. His arrival comes at an advanced stage of the company's developmen…
Crossject has reached a milestone. For the first time, the developer of the needle-free auto-injection device ZENEO® is on a clear operational path to…
Portzamparc, a subsidiary of BNP Paribas, has initiated coverage of Crossject stock with a 'Buy' recommendation and a target price of €4.50. This cove…
Portzamparc établit une recommandation d'achat sur Crossject et fixe un objectif de cours à 4,50 €.
